Antibodies to TNFα

Patent metadata

Field	Value
Publication number	US-9534046-B2
Application number	US-201514695949-A
Country	US
Kind code	B2
Filing date	Apr 24, 2015
Priority date	Dec 31, 2007
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

First claim

The invention claimed is:

1. An antibody capable of binding TNF-α, or an antigen binding portion thereof, which comprises, wherein the antibody is selected from the group consisting of:
(A) an antibody which comprises:
(a) a heavy chain, wherein the heavy chain comprises a heavy chain variable region (V H ) comprising the amino acid sequence SEQ ID NO:271; and
(b) a light chain, wherein the light chain comprises a light chain variable region (V L ) comprising the amino acid sequence SEQ ID NO:272; and

(B) an antibody which comprises:
(a) a heavy chain, wherein the heavy chain comprises a heavy chain variable region (V H ) comprising the amino acid sequence SEQ ID NO:453; and
(b) a light chain, wherein the light chain comprises a light chain variable region (V L ) comprising the amino acid sequence SEQ ID NO:454.

2. The antibody of claim 1 or the antigen binding portion thereof which comprises the V H comprising the amino acid sequence SEQ ID NO:271 and the V L comprising the amino acid sequence SEQ ID NO:272, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:269.

3. The antibody of claim 1 or the antigen binding portion thereof which comprises the V H comprising the amino acid sequence SEQ ID NO: 271 and the V L comprising the amino acid sequence SEQ ID NO:272, wherein the light chain comprises the amino acid sequence SEQ ID NO:270.

4. The antibody of claim 1 or the antigen binding portion thereof which comprises the V H comprising the amino acid sequence SEQ ID NO:453 and the V L comprising the amino acid sequence SEQ ID NO:454, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:451.

5. The antibody of claim 1 or the antigen binding portion thereof which comprises the V H comprising the amino acid sequence SEQ ID NO:453 and the V L comprising the amino acid sequence SEQ ID NO:454, wherein the light chain comprises the amino acid sequence SEQ ID NO:452.

6. The antigen binding portion of the antibody of claim 1 , wherein the antigen binding portion is selected from the group consisting of an Fab fragment, an F(ab′) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, an Fd fragment consisting of the VH and CH1 domains, an Fv fragment consisting of the VL and VH domains of a single arm of the antibody, a dAb fragment consisting of the V H domain, and an scFv.

7. The antibody of claim 1 or the antigen binding portion thereof, which is humanized.

8. A pharmaceutical composition comprising:
(a) the antibody of claim 1 or the antigen binding portion thereof; and
(b) a pharmaceutically acceptable carrier.

9. A nucleic acid molecule which encodes the antibody of claim 1 or the antigen binding portion thereof.

10. An expression vector comprising the nucleic acid molecule of claim 9 .

11. A host cell comprising a nucleic acid molecule which encodes the antibody of claim 1 or the antigen binding portion thereof.

12. A method for the production of an antibody or an antigen binding portion thereof, comprising:
(a) culturing of the host cell of claim 11 in a culture medium under conditions which permit expression of the antibody or binding portion thereof and its secretion into the culture medium; and
(b) recovering the antibody or binding portion thereof from the culture medium.

13. The pharmaceutical composition of claim 8 , wherein the antibody or the antigen binding portion thereof comprises the V H comprising the amino acid sequence SEQ ID NO:271 and the V L comprising the amino acid sequence SEQ ID NO:272, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:269.

14. The pharmaceutical composition of claim 8 , wherein the antibody or the antigen binding portion thereof comprises the V H comprising the amino acid sequence SEQ ID NO: 271 and the V L comprising the amino acid sequence SEQ ID NO:272, wherein the light chain comprises the amino acid sequence SEQ ID NO:270.

15. The pharmaceutical composition of claim 8 , wherein the antibody or the antigen binding portion thereof comprises the V H comprising the amino acid sequence SEQ ID NO:453 and the V L comprising the amino acid sequence SEQ ID NO:454, wherein the heavy chain comprises the amino acid sequence SEQ ID NO:451.

16. The pharmaceutical composition of claim 8 , wherein the antibody or the antigen binding portion thereof comprises the V H comprising the amino acid sequence SEQ ID NO:453 and the V L comprising the amino acid sequence SEQ ID NO:454, wherein the light chain comprises the amino acid sequence SEQ ID NO:452.

17. The pharmaceutical composition of claim 8 , wherein the antigen binding portion is selected from the group consisting of an Fab fragment, an F(ab′) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, an Fd fragment consisting of the VH and CH1 domains, an Fv fragment consisting of the VL and VH domains of a single arm of the antibody, a dAb fragment consisting of the V H domain, and an scFv.

18. The pharmaceutical composition of claim 8 , wherein the antibody or the antigen binding portion thereof is humanized.

Assignees

• Bayer Ip Gmbh

Inventors

• Votsmeier Christian
• Gritzan Uwe
• Kirchner Kornelia
• Strerath Michael
• Baral Kerstin
• Haupts Ulrich
• Coco Wayne M
• Steinig Susanne
• Scheidig Andreas
• Pellengahr Klaus
• Brückner Simone
• Plittersdorf Hanna
• Scholz Peter
• Tebbe Jan

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title